Skip to main content
Equibles
DMAC logo

DMAC · DiaMedica Therapeutics Inc.

Track DMAC — free

Use DMAC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DMAC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.68 -0.07 (-1.04%) At close · Aug 14
Market Cap
$360.22M
Shares
53.93M

DiaMedica Therapeutics Inc. Earnings Call Transcripts

Every quarterly earnings call for DiaMedica Therapeutics Inc. (DMAC) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-11
Second Quarter 2026 Financial Results Conference Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
DiaMedica Therapeutics Inc. Q1 FY2026 Earnings Call
Positive tone Preeclampsia clinical program Stroke ReMEDy2 trial Geographic trial expansion
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
DiaMedica Therapeutics Inc. Q4 FY2025 Earnings Call
Positive tone Preeclampsia program (DM199) Clinical trial enrollment / site expansion Stroke program (ReMEDy2)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
DiaMedica Therapeutics Inc. Q3 FY2025 Earnings Call
Confident tone Preeclampsia program and positive interim data U.S. Phase 2 preeclampsia trial planning Interim futility analysis timeline and sample size
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
DiaMedica Therapeutics Inc. Q2 FY2025 Earnings Call
Confident tone Preeclampsia Phase II interim results U.S. Phase IIb preeclampsia trial planning Preeclampsia program expansion and trial design
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
DiaMedica Therapeutics Inc. Q1 FY2025 Earnings Call
Confident tone Preeclampsia Phase 2 trial ReMEDy2 stroke program enrollment Clinical / regulatory milestones
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-17
DiaMedica Therapeutics Inc. Q4 FY2024 Earnings Call
Confident tone Preeclampsia program progress Clinical trial site activation MeVO/thrombectomy competitive landscape
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
DiaMedica Therapeutics Inc. Q3 FY2024 Earnings Call
Confident tone ReMEDy2 trial design changes Site activation and enrollment Preeclampsia program
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
DiaMedica Therapeutics Inc. Q2 FY2024 Earnings Call
Confident tone Preeclampsia program (DM-199) ReMEDy2 trial enrollment progress R&D expense growth
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
DiaMedica Therapeutics Inc. Q1 FY2024 Earnings Call
Positive tone ReMEDy2 Trial Site Activation and Enrollment Geographic Expansion of Trial Safety Profile of DM199
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
DiaMedica Therapeutics Inc. Q4 FY2023 Earnings Call
Positive tone ReMEDy2 trial enrollment progress DM199 clinical profile and stroke market opportunity PRA lawsuit and legal fees
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
DiaMedica Therapeutics Inc. Q3 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
DiaMedica Therapeutics Inc. Q2 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
DiaMedica Therapeutics Inc. Q1 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
DiaMedica Therapeutics Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-26
DiaMedica Therapeutics Inc. Q3 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
DiaMedica Therapeutics Inc. Q2 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
DiaMedica Therapeutics Inc. Q1 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-14
DiaMedica Therapeutics Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
DiaMedica Therapeutics Inc. Q3 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
DiaMedica Therapeutics Inc. Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
DiaMedica Therapeutics Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
DiaMedica Therapeutics Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
DiaMedica Therapeutics Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
DiaMedica Therapeutics Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-13
DiaMedica Therapeutics Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts CIK 1401040 CUSIP 25253X207 13F (30d) 84 filings 84 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)